新綸新材(002341.SZ):董事長兼總裁及其控制的企業擬增持不低於2000萬元的股份
格隆匯4月14日丨新綸新材(002341.SZ)公佈,公司於2022年4月13日收到公司董事長兼總裁廖垚及其控制的企業深圳市上元資本管理有限公司(“上元資本”)、公司董事兼常務副總裁李靖彬計劃增持公司股份的通知,基於對公司新材料領域業務增長的信心,廖垚及上元資本、李靖彬計劃自2022年4月15日起六個月內,以自有或自籌資金通過二級市場擇機增持公司股份,其中,廖垚及其控制的企業上元資本此次增持的金額合計不低於人民幣2000萬元;李靖彬此次增持的金額不低於人民幣15萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.